To compare the efficacy and safety of three different immunologic induction therapies in kidney transplantation of donation after cardiac death.

A retrospective analysis was carried out in clinical data of 121 renal transplant recipients who received transplantation in department of urology, the 309th hospital of PLA from January 2014 to January 2016. The recipients were divided into three groups according to the different immunologic induction drugs: basiliximab group (61 cases), rATG group (18 cases) and ATG-F group (42 cases). The occurrence of acute rejection, delayed graft function (DGF) and infection were observed.

Among 121 recipients, a total of 17 recipients occured acute rejection, including 10 recipients in basiliximab group, 2 recipients in rATG group and 5 recipients in ATG-F group, no statistical significance was found on occurrence rate of acute rejection (χ²=0.57, P>0.05). Thirty-two recipients occured DGF, including 16 recipients in basiliximab group, 6 recipients in rATG group and 10 recipients in ATG-F group, no statistical significance was found on occurrence rate of DGF (χ²=0.57, P>0.05). The occurrence rate of infection of basiliximab group , rATG group and ATG-F group were 14.8%, 22.2% and 26.2%, respectively, which had no statistical significance (χ²=2.12, P>0.05); the occurrence rate of CMV infection of rATG group and ATG-F group were both higher than basiliximab group (P all <0.017). The 1-year recipient and graft survival rate of basiliximab group , rATG group and ATG-F group were 96.7% and 95.1%、100.0% and 100.0%, 95.2% and 95.2%, respectively, which had no statistical significance (χ²=0.89, 0.91, P all>0.05).

The efficacy of basiliximab, rATG and ATG-F induction therapy in low-risk DCD transplantation did not different from each other, but rATG and ATG-F induction therapy were associated with an increased risk of CMV infection compared with basiliximab.